Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Non Operating Income (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Non Operating Income for 8 consecutive years, with $14.9 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income rose 68.68% year-over-year to $14.9 million; the TTM value through Mar 2026 reached $44.1 million, up 18.14%, while the annual FY2025 figure was $38.0 million, 0.72% up from the prior year.
  • Non Operating Income hit $14.9 million in Q1 2026 for Kymera Therapeutics, up from $10.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $14.9 million in Q1 2026 and bottomed at $249000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $6.8 million, with a median of $7.9 million recorded in 2025.
  • Year-over-year, Non Operating Income soared 3905.32% in 2022 and then dropped 10.38% in 2025.
  • Kymera Therapeutics' Non Operating Income stood at $3.8 million in 2022, then skyrocketed by 31.31% to $4.9 million in 2023, then skyrocketed by 102.33% to $10.0 million in 2024, then increased by 9.12% to $10.9 million in 2025, then soared by 36.69% to $14.9 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $14.9 million, $10.9 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.